Barclays PLC Sells 3,263 Shares of VanEck Pharmaceutical ETF (NASDAQ:PPH)

Barclays PLC lessened its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 73.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,173 shares of the company’s stock after selling 3,263 shares during the quarter. Barclays PLC’s holdings in VanEck Pharmaceutical ETF were worth $112,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of PPH. Jane Street Group LLC boosted its stake in shares of VanEck Pharmaceutical ETF by 124.0% during the 3rd quarter. Jane Street Group LLC now owns 19,436 shares of the company’s stock worth $1,847,000 after buying an additional 10,759 shares during the last quarter. Stifel Financial Corp raised its holdings in VanEck Pharmaceutical ETF by 13.4% during the third quarter. Stifel Financial Corp now owns 7,810 shares of the company’s stock worth $742,000 after acquiring an additional 924 shares in the last quarter. Miller Investment Management LP boosted its position in VanEck Pharmaceutical ETF by 13.4% during the third quarter. Miller Investment Management LP now owns 207,535 shares of the company’s stock valued at $19,722,000 after purchasing an additional 24,446 shares during the last quarter. Beck Capital Management LLC grew its stake in VanEck Pharmaceutical ETF by 5.2% in the third quarter. Beck Capital Management LLC now owns 22,383 shares of the company’s stock valued at $2,127,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Townsquare Capital LLC increased its position in shares of VanEck Pharmaceutical ETF by 3.8% during the 3rd quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after purchasing an additional 130 shares during the last quarter.

VanEck Pharmaceutical ETF Trading Up 1.1 %

NASDAQ PPH opened at $86.86 on Friday. VanEck Pharmaceutical ETF has a 12 month low of $83.74 and a 12 month high of $99.51. The stock has a 50 day moving average of $87.62 and a 200-day moving average of $91.99. The company has a market cap of $585.44 million, a PE ratio of 21.04 and a beta of 0.72.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently declared a dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 27th were paid a $0.411 dividend. The ex-dividend date of this dividend was Friday, December 27th. This is a boost from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.